Navigation Links
Heritage and Ipca Enter Into Strategic Alliance for Generic Pharmaceutical Products

EDISON, N.J., Aug. 27 /PRNewswire/ -- Heritage Pharmaceuticals Inc. ("Heritage") and Ipca Laboratories Ltd. ("Ipca") announced today that they have entered in to a strategic alliance for the development, supply and marketing of generic pharmaceutical products for the U.S. prescription drug market. Under the Agreement, Ipca shall develop and register selected products for U.S. ANDA submission and Heritage retains sales and marketing rights to such products. The parties shall share net profits from the sales proceeds post-launch.

Commenting on the Agreement, Heritage President & CEO, Jeffrey Glazer, stated, "Our agreement with Ipca represents yet another important strategic partnership with an emerging, low cost developer and supplier of active ingredients and finished goods. These types of agreements enable Heritage to leverage our business model of strategic outsourcing to obtain a "virtually vertical" supply chain of quality generic products as we continue to expand our product offerings."

Heritage Pharmaceuticals Inc. is an emerging generic pharmaceutical company engaged in the acquisition, licensing, development, marketing, sale and distribution of generic pharmaceutical products for the global prescription drug markets. Heritage launched its U.S. label in 2006 and currently markets 3 products over 10 SKU's. The Company will continue to introduce its acquired multi-source generic product line during 2007-08 following its tradition of premier quality, value and service in generics.

Ipca Laboratories Ltd. is a fast growing fully integrated pharmaceutical company based in Mumbai, India engaged in the manufacturing and marketing of a range of pharmaceuticals with a thrust on international business. Ipca exports its Active Pharmaceutical Ingredients and Finished Dosages to over 110 countries across the globe, which contributed about 53% of the Company's total global income of $227mm in the financial year 2006-07. It has a strong focus on international business in the developed markets like Europe and North America.

SOURCE Heritage Pharmaceuticals Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. NanoRite Innovation Center opens with small science, big promise
2. UW-Madison to receive $125M for bioenergy research center
3. WARF enters licensing agreements for stem cell products
4. Internet-enabled niche markets take center stage
5. Virent enters agreement with Shell Oil unit to make hydrogen with biomass
6. TomoTherapy opens technical training center
7. Stem cell and regenerative medicine center to aid education and commerce
8. Mega-Metro Center may go beyond Chicago and Wisconsin
9. Software company enters health space with RFID solutions on hold
10. Former Fiserv exec to enter Business Hall of Fame
11. Berbee to expand at New Venture Center
Post Your Comments:
(Date:11/27/2015)... ... November 27, 2015 , ... ... that includes over 2,000 technical presentations offered in symposia, oral sessions, workshops, awards, ... spectroscopy, covers a wide range of applications such as, but not limited to, ...
(Date:11/25/2015)... , November 26, 2015 ... Biobanking Market 2016 - 2020 report analyzes that ... integrity and quality in long-term samples, minimizing manual ... cost-effectiveness. Automation minimizes manual errors such as mislabeling ... efficiency. Further, it plays a vital role in ...
(Date:11/25/2015)... and HOLLISTON, Mass. , Nov. 25, ... HART ), a biotechnology company developing bioengineered organ ... Jim McGorry will present at the LD Micro ... at 2:30 p.m. PT. The presentation will be webcast ... days. Management will also be available at the conference ...
(Date:11/25/2015)... SAN DIEGO , Nov. 25, 2015 ... that management will participate in a fireside chat discussion ... New York . The discussion is ... Time. .  A replay will ... Contact:  Media Contact:McDavid Stilwell  , Julie NormartVP, Corporate ...
Breaking Biology Technology:
(Date:11/10/2015)... , Nov. 10, 2015 ... biometrics that helps to identify and verify the ... is considered as the secure and accurate method ... of a particular individual because each individual,s signature ... results especially when dynamic signature of an individual ...
(Date:11/2/2015)... 2015  SRI International has been awarded a contract ... services to the National Cancer Institute (NCI) PREVENT Cancer ... expertise, modern testing and support facilities, and analytical instrumentation ... toxicology studies to evaluate potential cancer prevention drugs. ... Cancer Drug Development Program is an NCI-supported pipeline to ...
(Date:10/29/2015)... Oct. 29, 2015  Rubicon Genomics, Inc., today ... distribution of its DNA library preparation products, including ... new ThruPLEX Plasma-seq kit. ThruPLEX Plasma-seq has been ... of NGS libraries for liquid biopsies--the analysis of ... prognostic applications in cancer and other conditions. Eurofins ...
Breaking Biology News(10 mins):